WUXI BIOLGCS ADRに関するコメント

Hong Kong stocks opened lower in the morning session. $Hang Seng Index(800000.HK)$ opened 109 points or 0.7% lower at 16,628. $Hang Seng China Enterprises Index(800100.HK)$ opened 40 points or 0.7% lower at 5,807. $Hang Seng TECH Index(800700.HK)$ opened 40 points or 1.1% lower at 3,554.
$無錫薬明康徳(02359.HK)$ , whose net profit rose 21% in 2023, delayed two placing-funded investment projects by 2 years to the end of 2025, and its share price lost 2.8% to $41.55, while its sa...

There was HKD361.9 million and HKD52.1 million Southbound Trading net inflow to $中国移動(00941.HK)$ and $京基金融(01468.HK)$ .
There was HKD505.7 million, HKD372.6 million and HKD147.1 million Southbound Trading net outflow from $美団点評(03690.HK)$ , $テンセント(00700.HK)$ and $中国海洋石油(00883.HK)$ .
For $SH->HK コネクト(GangGuTong.HK)$ , $中国銀行(03988.HK)$ was the most active stock with highest net inflow of ...

$Hang Seng Index(800000.HK)$ falls by 2%, and $Hang Seng TECH Index(800700.HK)$ is now down 2.8%.
$無錫薬明康徳(02359.HK)$ tumbled by 5% and $薬明生物(02269.HK)$ was down 6.7%. Biotechnology Innovation Organization revised the announcement to WuXi Apptec proactively ending its relationship with BIO.

ln a press release Wednesday afternoon, the Biotechnology Innovation Organization said it will take steps to separate from WuXi—AppTec regarding membership and support the BIOSECURE Act.
$薬明生物(02269.HK)$$無錫薬明康徳(02359.HK)$

Wuxi Bio announced that the company noted that a procedural hearing about a revised draft bill was held by the U.S. Senate.
Wuxi Bio's share price extended further decline to 21% in HK in the afternoon session.
The company reiterated that it is not a subsidiary of WUXI Apptec and does not have a human genomics business, nor does it collect human genomic data in any of its businesses.
$薬明生物(02269.HK)$$無錫薬明康徳(02359.HK)$

$薬明生物(02269.HK)$ Short selleres cleared 17% of their positions!

$薬明生物(02269.HK)$ The proposed bill need to be agreed at committee level before submitting to house then senate and lastly president approval. It is lengthy process and required a long time frame before become effective law! Moreover, the proposed law is abt restricting federal fund which had very limited effect to current Wuxi Bio biz. The bill is cocern abt US citizen data being used caused national security concern which Wuxi Bio never has or used it in its daily biz.

$薬明生物(02269.HK)$
Wuxi Bio had clarified its CEO false claim - he only ever given a one-time guest lecturer back to 2013!

$薬明生物(02269.HK)$
Wuxi Bio had clarified that that it is not subsidiary of Wuxi Ming Kand. So, the congrssman needs to amend their proposal!